Cancer-Killing virus trial shows promise for Hard-to-Treat tumors
NCT ID NCT04695327
First seen Mar 16, 2026 · Last updated May 14, 2026 · Updated 13 times
Summary
This early-stage trial tested a modified virus called TILT-123 in 32 people with advanced solid tumors that had not responded to standard treatments. The virus is designed to infect and kill cancer cells while also boosting the immune system. The main goal was to check safety and find the right dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Docrates Cancer Center
Helsinki, Uusima, 00180, Finland
-
Helsinki University Hospital
Helsinki, Uusima, 00029, Finland
Conditions
Explore the condition pages connected to this study.